View in EDS

Safety of switching to Migalastat from enzyme replacement therapy in Fabry disease: Experience from the Phase 3 ATTRACT study.

Saved in:
Bibliographic Details
Title: Safety of switching to Migalastat from enzyme replacement therapy in Fabry disease: Experience from the Phase 3 ATTRACT study.
Authors: Hughes, Derralynn A.1, rmgvdah@ucl.ac.uk, Nicholls, Kathleen2, Sunder‐Plassmann, Gere3, Jovanovic, Ana4, Feldt‐Rasmussen, Ulla5, Schiffmann, Raphael6, Giugliani, Robert7, Jain, Vipul8, Viereck, Chris8, Castelli, Jeffrey P.8, Skuban, Nina8, Barth, Jay A.8, Bichet, Daniel G.9
Source: American Journal of Medical Genetics. Part A; Jun2019, Vol. 179 Issue 6, p1069-1073, 5p
Database: Applied Science & Technology Source
Be the first to leave a comment!
You must be logged in first